StockData
IN8bio, Inc. logo

IN8bio, Inc. (INAB) stock

INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.82+0.00 (+0.49%)

Close on Nov 17, 2026Market cap $8.08MP/E –Yield –

IN8bio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

IN8bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$14.36M. For fiscal 2025 it was -$12.71M. The highest annual figure on record is -$7.13M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.71M–
FY2024Dec 31, 2024-$24.15M–
FY2023Dec 31, 2023-$23.34M–
FY2022Dec 31, 2022-$24.12M–
FY2021Dec 31, 2021-$13.51M–
FY2020Dec 31, 2020-$7.13M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.75M–
Q1 FY2026Mar 31, 2026-$4.95M–
Q4 FY2025Dec 31, 2025-$2.14M–
Q3 FY2025Sep 30, 2025-$3.52M–
Q2 FY2025Jun 30, 2025-$3.93M–
Q1 FY2025Mar 31, 2025-$3.12M–
Q4 FY2024Dec 31, 2024-$4.03M–
Q3 FY2024Sep 30, 2024-$6.11M–
Q2 FY2024Jun 30, 2024-$6.09M–
Q1 FY2024Mar 31, 2024-$7.92M–
Q4 FY2023Dec 31, 2023-$4.85M–
Q3 FY2023Sep 30, 2023-$5.71M–
Q2 FY2023Jun 30, 2023-$5.34M–
Q1 FY2023Mar 31, 2023-$7.44M–
Q4 FY2022Dec 31, 2022-$7.95M–
Q3 FY2022Sep 30, 2022-$5.74M–
Q2 FY2022Jun 30, 2022-$5.87M–
Q1 FY2022Mar 31, 2022-$4.56M–
Q4 FY2021Dec 31, 2021-$2.18M–
Q3 FY2021Sep 30, 2021-$6.37M–
Q2 FY2021Jun 30, 2021-$2.46M–
Q1 FY2021Mar 31, 2021-$2.51M–
Q4 FY2020Dec 31, 2020-$1.73M–
Q3 FY2020Sep 30, 2020-$2.12M–

More IN8bio figures

See a number that looks wrong?